2021
DOI: 10.2174/1381612826666201023144836
|View full text |Cite
|
Sign up to set email alerts
|

Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review

Abstract: : Combination therapy involving different therapeutic strategies mostly provides more rapid and effective results as compared to monotherapy in diverse areas of clinical practice. The most worldwide famous acetylcholinesterase inhibitor (AChEIs) donepezil for its dominant role in Alzheimer’s disease (AD) has also attracted the eyes of many pharmaceuticals regarding its promising pharmacological potencies such as neuroprotective, muscle relaxant, and sleep. Recently a combination of donepezil with other agents … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
20
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 37 publications
(20 citation statements)
references
References 59 publications
0
20
0
Order By: Relevance
“…The commonly used anti-AD drugs (donepezil and rivastigmine) seem as viable alternatives (Karasova et al 2020a, b). Their toxicity, brain distribution, and adverse effects have been thoroughly explored (Bures et al 2020(Bures et al , 2021Korabecny et al 2019;Nguyen et al 2021;Rong et al 2021;Valis et al 2017;Zemek et al 2014). While pyridostigmine administered alone failed, donepezil decreased soman's acute toxicity significantly (the protective ratio 1.35).…”
Section: Discussionmentioning
confidence: 99%
“…The commonly used anti-AD drugs (donepezil and rivastigmine) seem as viable alternatives (Karasova et al 2020a, b). Their toxicity, brain distribution, and adverse effects have been thoroughly explored (Bures et al 2020(Bures et al , 2021Korabecny et al 2019;Nguyen et al 2021;Rong et al 2021;Valis et al 2017;Zemek et al 2014). While pyridostigmine administered alone failed, donepezil decreased soman's acute toxicity significantly (the protective ratio 1.35).…”
Section: Discussionmentioning
confidence: 99%
“…Gilead Sciences developed it for Ebola infection in 2017. Remdesivir, for example, can repress SARS-CoV and MERS-CoV replication in in vitro studies (Rong et al 2021 ; Agostini et al 2018 ). Remdesivir represses movement using human CoV receptors of bat CoV, SARS-CoV, and MERS-CoV strains, which can replicate in human epithelial cells and function like intermediate channels.…”
Section: Potential Treatmentsmentioning
confidence: 99%
“…Acetylcholinesterase (AChE) inhibitors have recently been shown to be an effective clinical strategy for preserving acetylcholine levels and improving cholinergic activity, as stated by Colovic et al [ 98 ]. Inhibiting AChE and Butyrylcholinesterase (BChE) has developed into a standard method for treating the symptoms of neurodegenerative diseases like Alzheimer’s disease [ 99 ].…”
Section: Biological Activities Of Genus Scutellariamentioning
confidence: 99%